<DOC>
	<DOCNO>NCT00557011</DOCNO>
	<brief_summary>The purpose study ass , control environment , efficacy safety NRP104 Adderall XR compare placebo treatment child , age 6-12 , ADHD .</brief_summary>
	<brief_title>NRP104 , Adderall XR Placebo Children Aged 6-12 Years With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>male nonpregnant female , age 612 year DSMIVTR criterion diagnosis ADHD , combine hyperactiveimpulsive subtypes stable regimen stimulant least one month last six month show adequate response stimulant without unacceptable side effect comorbid psychiatric diagnosis psychosis , bipolar illness , severe OCD , severe depressive anxiety disorder history seizure last 2 year , tic disorder Tourette 's clinically significant ECG laboratory abnormality screen baseline take clonidine anticonvulsant drug take medication affect blood pressure heart rate</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>